Trial Profile
A randomized, single blind, comparative, three way crossover clinical study to evaluate the efficacy and safety of a novel nasal spray (FDC of Azelastine hydrochloride and Mometasone furoate monohydrate) compared to its individual components Azelastine hydrochloride 137 mcg and Mometasone furoate monohydrate 50 mcg nasal sprays in patients suffering from perennial Allergic Rhinitis.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Azelastine/mometasone (Primary) ; Azelastine; Mometasone
- Indications Perennial allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Cipla
- 19 Mar 2014 New trial record